APLLTD
Alembic Pharmaceuticals Limited (APLLTD) Stock Analysis
Alembic Pharmaceuticals Limited is an Indian pharma company focused on formulations in chronic therapies and international markets. It develops and markets generic medicines in the US, India, and other regulated countries. The company has R&D and manufacturing facilities in India. It is a listed large-cap pharmaceutical stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹792.50
-4.96% 1W | -14.00% 52W
Market Cap
15.6k CR
P/E Ratio
22.7
52W High
₹998
52W Low
₹635.8
Div. Yield
1.5%
Beta
0.3
50 DMA
₹825
200 DMA
₹776
Profit Margin
8.9%
Inst. Own.
16.6%
📈 CONSOLIDATING UP
📈 CONSOLIDATING UP
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Expenses | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% |
| Other Income | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before tax | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% |
| Net Profit | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS in Rs | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 |
| Expenses | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 6,224 | 6,617 |
| Operating Profit | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,121 | 1,167 |
| OPM % | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 15% | 15% |
| Other Income | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | -14 | -1 |
| Interest | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 | 98 |
| Depreciation | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 | 342 |
| Profit before tax | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 694 | 726 |
| Tax % | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | 3% | 18% | 3% | |
| Net Profit | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS in Rs | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 | 35.27 |
| Dividend Payout % | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | 35% | 37% | 35% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 9.0% | 6.0% | 9.0% |
| Profit CAGR | 28.0% | -9.0% | 0.0% |
Shareholding Pattern
Promoters69.68%
FIIs3.96%
DIIs16.46%
Public9.91%
Promoters69.74%
FIIs4.04%
DIIs16.30%
Public9.92%
Promoters69.74%
FIIs4.23%
DIIs16.17%
Public9.84%
Promoters69.74%
FIIs4.26%
DIIs16.17%
Public9.83%
Promoters69.87%
FIIs4.17%
DIIs15.93%
Public10.00%
Promoters69.61%
FIIs4.55%
DIIs13.32%
Public12.53%
Promoters69.61%
FIIs4.46%
DIIs15.39%
Public10.54%
Promoters69.67%
FIIs3.94%
DIIs16.43%
Public9.96%
Promoters69.74%
FIIs4.26%
DIIs16.17%
Public9.83%
Promoters69.87%
FIIs4.17%
DIIs15.93%
Public10.00%
APLLTD
Holdings Analysis
Key strengths & risk signals
74
Overall
81
Fundamental
68
Technical
Risks (4)
LOW MARGIN! 8.9% profit margin - thin profits.
RECOVERY MODE! Current price (792.5) above 200-day but below 50-day.
WEAK YEAR! Stock declined 14.0% in the last year.
NEGATIVE MOMENTUM! Price declined across timeframes - down 5.0% (1 week), 2.3% (1 month), 5.6% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.89 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (825.0) is above 200-day average (776.0) - positive signal.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 241,079 vs down days: 164,901. Ratio: 1.46x
Fundamental & Technical Analysis
74Overall
81Fundamental
68Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 9.5% (MODERATE, 8/15). Profit CAGR: 25.4% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 8.9% profit margin - thin profits.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.89 indicates stock is cheap relative to growth.
Dividend Yield
5/10
LOW DIVIDEND! 1.5% yield - minimal income contribution.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.24 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 12.39% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (825.0) is above 200-day average (776.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (792.5) above 200-day but below 50-day.
Trend Pattern
14/20
Current trend: CONSOLIDATING UP
52W Performance
2/10
WEAK YEAR! Stock declined 14.0% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 241,079 vs down days: 164,901. Ratio: 1.46x
RSI
4/5
APPROACHING OVERSOLD! RSI at 39.3 - watch for reversal.
52W Range
3/5
MID RANGE! Trading at 43.3% of 52W range - neutral zone.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 5.0% (1 week), 2.3% (1 month), 5.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
APLLTD
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-10 | Concall PDF | |
| Q4FY262026-05-21 | Concall PDF | |
| Q3FY262026-02-11 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| NATCOPHARM | ₹782.60 | 12.4 | 32.8% | 14.5% | 25.6% | -3.8% | 66 | BREAKDOWN | -57.0% | -22.9% | -44.7% | -0.5% |
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
Data from TradeAlone · Updated daily
APLLTD News
Alembic Pharmaceuticals Limited (aplltd) Q1 FY27: Revenue Surges 26% Yoy2026-08-04Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Prucalopride Tablets2026-07-28Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Final Approval for Dapsone Gel, 5%2026-06-26Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Final Approval for Oseltamivir Phosphate Oral Suspension2026-06-26Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Final Approval for Tretinoin Cream USP, 0.05%2026-06-12Alembic Pharmaceuticals Limited (aplltd) Receives USFDA Tentative Approval for Larotrectinib Capsules2026-06-11Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Final Approval for Haloperidol Tablets2026-06-05Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Final Approval for Levothyroxine Sodium Tablets2026-05-22Alembic Pharmaceuticals Limited (aplltd) Q4 FY26: Revenue Up 4%, Strong Growth in US Formulation2026-05-15Alembic Pharmaceuticals Limited (aplltd) Secures USFDA Tentative Approval for Darolutamide Tablets, 300 Mg2026-05-14
